newsfilter
← Latest News
Business Wire·

Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

IVERIC bio, Inc. (NASDAQ:ISEE) announced today that top-line efficacy and safety results from GATHER2, the Company's second Phase 3 clinical trial of avacincaptad pegol (ACP, also known as Zimura®), an investigational complement C5 inhibitor bein